Graft-versus-host disease (GVHD) is
Introduction
In the past, graft-versus-host disease (GVHD) was simply felt to be due to a T cell activation from minor antigen mismatches between the donor and host. It has since become clear that GVHD is far more complicated and will probably require a complicated therapeutic approach. The very complexity of GVHD affords the opportunity to treat it by attacking its many different levels. When considering the etiology of GVHD, one should begin with the recipient conditioning. The tissue damage that occurs during the conditioning regimen is probably one of the main factors that will trigger and drive GVHD. The direct effects of preparative regimens on end organ tissues, such as the liver and small intestine, and the ensuing secretion of inflammatory cytokines, such as tumor necrosis factor (TNF) and lipopolysaccharide, are important in the genesis of the GVHD process.
Recipient conditioning
One area that appeared promising for some time, and may be returning to the forefront, is the use of drugs directed against TNF production. An anti-TNF monoclonal agent has recently become commercially available, although there are supply issues due to production difficulties. Other pharmacologic agents that inhibit TNF production, including inhibitors of phosphodiesterase, may also prove useful in this setting.
Recently, the importance of interleukin-11 (IL-11) in the pathophysiology of acute GVHD has been elucidated. In an animal model of GVHD in which animals were given IL-11 as a gut protector from days 2 to 10, the survival in the mismatched animals was identical to that in the syngeneic controls. Animals receiving control diluent all essentially succumbed to their GVHD. 1 In the IL-11-treated animal, the gut endothelium remained intact and therefore the release of inflammatory cytokines was decreased. IL-11 also shifted the TH1/TH2 balance to a TH2+ cell population. Thus, not only was there gut protection, but the IL-11 was also probably Correspondence: GB Vogelsang Received 26 October 1999; accepted 2 November 1999 inducing tolerance, suggesting a possible future role for the molecule in GVHD prophylaxis.
The use of nonmyeloablative preparative regimens has been undertaken in an attempt to decrease GVHD. Slavin et al 2 were the first to report this approach in a large group of patients. Twenty-six patients, 19 of whom were good risk, were given a preparative regimen of busulfan, fludarabine, ATG, and cyclosporin. Not all of the patients had white counts that dropped to zero, nor did they all require platelet transfusions. The median survival at 14 months was 80%; the median patient age was in the early 30s. Thus, although the results may not be generalizable to a typical adult transplant population, this approach is promising.
Donor leukocyte infusions (DLI) have recently been studied in the context of achieving a graft-versus-tumor effect. 3 Patients were pretreated with interferon and then given DLI. In the first group of 18 patients, only three had sustained engraftment, and all three had received prior autologous transplants. Six of the patients were given cytoxan or ara-C preconditioning, followed by an additional DLI, and only one of these patients had sustained engraftment. The only patients who demonstrated antitumor benefit were those who developed GVHD. These studies indicate that the use of DLI to sustain the graft-versus-tumor effect may be effective in selected patients, especially those with slow-growing tumors that are particularly immunoresponsive.
Donor T cell activation
Research in the area of donor T cell activation has been stimulated by the availability of LF 08-0299 (Tresperimus; Fournier). Although the mechanism by which this drug acts is not well-understood, it seems to very selectively induce anergy post-transplant and has been used to treat GVHD in animal models. An ongoing multicenter clinical trial is assessing the use of Tresperimus as part of a GVHD prophylaxis regimen in patients with high-risk malignancies undergoing transplantation.
Copaxone, another compound shown to prevent donor T cell activation has recently entered phase I clinical trials. Copaxone (Teva) has been shown to block the MHC class II antigen in a very promiscuous fashion. 4 When animals were treated with this compound, the rate of GVHD decreased and the survival rate improved. However, the treatment was performed over a protracted period of time and the goal of induction of tolerance in these animals was not fully achieved. Nonetheless, these studies demonstrated that altering T cell activation by blocking class II antigens might diminish the severity of GVHD.
Another group of agents demonstrating activity in GVHD has been monoclonal antibodies directed against T cell epitopes. Recent data have been described from groups at Memorial Sloan-Kettering and MD Anderson on the use of anti-TAC antibody (daclizumab; Zenepax; Roche) for treatment of patients with steroid refractory GVHD (personal communication, Nancy Kernan). In this study, the initial cohort received 1 mg/kg of anti-TAC on days 1, 8, 15, 22 and 29. Patients who had not achieved a CR by the end of the first week also received ATG. In the second group, an additional dose of anti-TAC was added at day 4, since it had been observed that between day 1 and day 8 many patients were flaring with GVHD. With this modified schedule, there was a 47% CR rate with administration of just the antibody. Studies are underway at Johns Hopkins and Memorial Sloan-Kettering to evaluate monoclonal therapy earlier on in the course of the GVHD therapy. The initial study will try to better define the proper dosing schedule before a larger, multi-institutional study will evaluate steroids with or without the addition of anti-TAC for initial therapy of anti-GVHD. This study should better evaluate the eventual role of this monoclonal antibody.
In another trial, Anasetti et al 5 looked at the use of this monoclonal in initial prophylaxis of patients receiving matched unrelated donor transplants, but was not able to show a benefit. In addition, investigators are conjugating the monoclonals to toxin moieties in order to enhance their effect.
Effector cells
How can the effector cells be treated once the T cells have been activated? In this context, rapamycin, has garnered interest. Clinical trials are underway, but no results have been reported in marrow transplants. In animal studies using rapamycin, most of the animals survived, but had histopathologic evidence of ongoing GVHD. It is suggested that rapamycin may prevent the effector cell expansion without actually controlling the alloreactivity, so that these cells were still pumping out cytokines without affecting the basic underlying process.
Future directions
The use of nucleoside analogues to selectively eliminate alloreactive T cells has recently been explored in treatment of GVHD. Initial studies with fludarabine at chemotherapy dosing schedules resulted in significant toxicity and were not pursued in organized trials. However, interest has been renewed after recent reports of decreased GVHD in patients who received fludarabine as part of their conditioning regimen. 6 It may be that fludarabine somehow affects the immunologic recovery after the transplant or is less toxic to end organs than traditional conditioning regimens, resulting in less cytokine production.
Pentostatin, another purine analog which may be less myelosuppressive than fludarabine and therefore might be better tolerated for transplant, is also being explored in GVHD. A clinical trial has been initiated to study the pharmacokinetics and effect on T cell populations of pentostatin in patients with GVHD. The goal of this study is to determine a rational dosing schedule before advancing the drug in clinical trials. Thus far, all of the patients have achieved at least a partial response, which is especially encouraging given the extent of pretreatment. To explore the immunologic effects of purine analogs, it is extremely likely that dosing schedules different from chemotherapeutic regimens will be optimal.
In summary, a number of novel agents have been used to target various aspects in GVHD. With the use of these immunomodulatory agents, we also must worry about how the graft-versus-leukemia component of the transplant will be affected. It appears that GVHD may be best attacked sequentially in order to control it once it occurs.
